

Follicular Lymphoma

Untreated Follicular Lymphoma Treated With ObinituzumAb in a Non-interventional Study (URBAN)

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT04034056 ML41215

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

To evaluate the effectiveness and safety of obinituzumab in clinical routine in 1L FL measured by the % of relapse within 24 months from start of therapy.

Hoffmann-La Roche
Sponsor

N/A
Phase

NCT04034056 ML41215
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
